45
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Review of Recent Laboratory and Experimental Data on Cardiotoxicity of Statins

      Journal of Cardiovascular Development and Disease
      MDPI AG

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Due to the fact that statins are among the most high-demand therapeutic agents used for the treatment and prevention of the most common cardiovascular diseases, a significant amount of research is focused on these drugs. As a result, the study and discovery of new effects in statin drugs continues. Research methods are constantly being improved in terms of their sensitivity and specificity, which leads to a change in ideas. In addition to the main lipid-lowering effect, statins have a number of additional effects, which can be conditionally divided into positive (pleiotropic) and negative (side effects). Moreover, information about many of the pleiotropic effects of statins is controversial and may subsequently change as new data become available. To a large extent, this is due to the introduction of new and the improvement of old methods of study: clinical, laboratory and morphological ones. Recent studies report the possibility of statins having potential cardiotoxic properties, which is expressed by an increase in the concentration of highly sensitive cardiac troponins, as well as various adverse changes in cardiac myocytes at the ultrastructural and molecular levels. This paper discusses possible mechanisms of statin cardiotoxicity. This narrative review is based on an analysis of publications in the Medline, PubMed, PubMed Central and Embase databases. The terms “statins”, “troponin”, “troponin I”, “troponin T” in combination with “cardiotoxicity”, “false positive”, “mechanisms of increase”, “pathophysiological mechanisms”, “oxidative stress” and “cardiomyocyte apoptosis” were used to search publications.

          Related collections

          Most cited references94

          • Record: found
          • Abstract: found
          • Article: not found

          Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

          Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain.
            • Record: found
            • Abstract: not found
            • Article: not found

            OUP accepted manuscript

            (2020)
              • Record: found
              • Abstract: found
              • Article: not found

              Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

              Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.

                Author and article information

                Contributors
                (View ORCID Profile)
                Journal
                JCDDB4
                Journal of Cardiovascular Development and Disease
                JCDD
                MDPI AG
                2308-3425
                November 2022
                November 19 2022
                : 9
                : 11
                : 403
                Article
                10.3390/jcdd9110403
                9696927
                36421938
                4597004c-02b6-480e-b4e9-ab6708dab0b9
                © 2022

                https://creativecommons.org/licenses/by/4.0/

                History

                Comments

                Comment on this article

                Related Documents Log